Pfizer and Merck are among the drugmakers with enough cash on hand to invest $10 billion or more in mergers and acquisitions this year. However, expiring patents on blockbuster drugs, more muscular biotechnology companies and stronger competition might impede Big Pharma's ability to conclude large deals, an Ernst & Young analysis found.
Big Pharma deals may lie ahead in 2013
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||